Cardiovascular toxicities of therapy for genitourinary malignancies

Research output: Contribution to journalReview article

Authors

External Institution(s)

  • University of Pennsylvania

Details

Original languageEnglish (US)
Pages (from-to)121-128
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume38
Issue number3
StatusPublished - Mar 2020
Peer-reviewedYes

Abstract

The cardiovascular consequences of systemic cancer therapies are becoming increasingly important for the growing population of patients living with cancer. In particular, patients with genitourinary malignancies are at significant risk for cardiovascular toxicities, due to both prevalent underlying risk factors and the known adverse effects of commonly used therapies. Moreover, improving survival outcomes and novel combination treatment approaches for genitourinary malignancies may predispose to a growing risk for cardiovascular morbidity. As such, knowledge of these potential cardiovascular risks is essential for the optimal care of these patients. This review highlights the cardiovascular toxicities associated with common therapeutic agents for genitourinary malignancies.

    Research areas

  • Cardiovascular toxicity, Genitourinary cancers, Survivorship

Citation formats

APA

Narayan, V., Vaughn, D. J., & Ky, B. (2020). Cardiovascular toxicities of therapy for genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 38(3), 121-128. https://doi.org/10.1016/j.urolonc.2019.04.029

Harvard

Narayan, V, Vaughn, DJ & Ky, B 2020, 'Cardiovascular toxicities of therapy for genitourinary malignancies', Urologic Oncology: Seminars and Original Investigations, vol. 38, no. 3, pp. 121-128. https://doi.org/10.1016/j.urolonc.2019.04.029